Template:Lipid modifying agents: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
m 1 revision imported |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{Navbox | {{Navbox | ||
| name = Lipid modifying agents | | name = Lipid modifying agents | ||
| title = [[Hypolipidemic agent|Lipid- | | title = [[Hypolipidemic agent|Lipid-lowering agents]] ([[ATC code C10|C10]]) | ||
| state = {{{state<includeonly>|autocollapse</includeonly>}}} | | state = {{{state<includeonly>|autocollapse</includeonly>}}} | ||
| listclass = hlist | | listclass = hlist | ||
| Line 11: | Line 11: | ||
| list1 = | | list1 = | ||
* [[Ezetimibe]] | * [[Ezetimibe]] | ||
* [[Hyzetimibe]] | |||
* [[SCH-48461]] | * [[SCH-48461]] | ||
| Line 20: | Line 21: | ||
* [[Colestyramine]] | * [[Colestyramine]] | ||
* [[Colextran]] | * [[Colextran]] | ||
* [[Dietary fiber|Soluble fiber]] such as [[psyllium]] and [[glucomannan]] | |||
}} | }} | ||
| Line 42: | Line 43: | ||
* [[Acipimox]] | * [[Acipimox]] | ||
* [[Aluminium nicotinate]] | * [[Aluminium nicotinate]] | ||
* [[ | * [[Nicotinic acid]] | ||
* [[Niceritrol]] | * [[Niceritrol]] | ||
* [[Nicofuranose]] | * [[Nicofuranose]] | ||
| Line 56: | Line 57: | ||
| list4 = | | list4 = | ||
* [[Bempedoic acid]] | * [[Bempedoic acid]] | ||
|group5= [[Thyromimetic]]s (VLDL) | |||
|list5= | |||
* [[Dextrothyroxine]]<sup>‡</sup> | |||
*[[Resmetirom]] | |||
}} | }} | ||
| Line 63: | Line 67: | ||
| evenodd = swap | | evenodd = swap | ||
| group1 = [[ | | group1 = [[PPAR agonist]]s (LDL) | ||
| list1 = | | list1 = | ||
{{Navbox|child | |||
| group1 = [[Fibrate]]s | |||
| list1 = | |||
* [[Aluminium clofibrate]] | * [[Aluminium clofibrate]] | ||
* [[Bezafibrate]] | * [[Bezafibrate]] | ||
| Line 75: | Line 83: | ||
* [[Fenofibrate]] | * [[Fenofibrate]] | ||
* [[Gemfibrozil]] | * [[Gemfibrozil]] | ||
* [[Nafenopin]] | |||
* [[Pemafibrate]] | * [[Pemafibrate]] | ||
* [[Ronifibrate]] | * [[Ronifibrate]] | ||
* [[Simfibrate]] | * [[Simfibrate]] | ||
|group2=Others | |||
|list2= | |||
*[[GW501516]]<sup>§</sup> | |||
}} | |||
| group2 = [[CETP inhibitor]]s ([[High-density lipoprotein|HDL]]) | | group2 = [[CETP inhibitor]]s ([[High-density lipoprotein|HDL]]) | ||
| list2 = | | list2 = | ||
| Line 92: | Line 104: | ||
* [[Bococizumab]] | * [[Bococizumab]] | ||
* [[Evolocumab]] | * [[Evolocumab]] | ||
* [[Inclisiran]] | |||
| group4 = [[ANGPTL3]] inhibitors ([[Low-density lipoprotein|LDL]]/[[High-density lipoprotein|HDL]]) | |||
| list4 = | |||
* [[Evinacumab]] | |||
}} | }} | ||
| Line 115: | Line 132: | ||
* [[Benfluorex]]<sup>‡</sup> | * [[Benfluorex]]<sup>‡</sup> | ||
* [[Darapladib]]<sup>§</sup> | * [[Darapladib]]<sup>§</sup> | ||
* [[Lapaquistat]]<sup>§</sup> | * [[Lapaquistat]]<sup>§</sup> | ||
* [[Magnesium pyridoxal 5-phosphate glutamate]] | * [[Magnesium pyridoxal 5-phosphate glutamate]] | ||
* [[Meglutol]] | * [[Meglutol]] | ||
* [[Mipomersen]] | * [[Mipomersen]] | ||
* [[Omega-3- | * [[Omega-3-acid ethyl esters|Omega−3-acid ethyl esters]] | ||
* [[Policosanol]] | * [[Policosanol]] | ||
* [[Probucol]] | * [[Probucol]] | ||
| Line 133: | Line 149: | ||
[[Category:Drug templates by ATC]] | [[Category:Drug templates by ATC]] | ||
</noinclude> | </noinclude> | ||
Latest revision as of 19:30, 8 March 2025
| Lipid-lowering agents (C10) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
